Literature DB >> 7896458

Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis.

R C Bargou1, P T Daniel, M Y Mapara, K Bommert, C Wagener, B Kallinich, H D Royer, B Dörken.   

Abstract

We have studied the expression of the apoptosis-regulating genes bcl-2, bcl-x, bax and APO-1/fas (CD95) in human breast cancer. The expression pattern of these genes in human breast-cancer tissues and breast-cancer-derived cell lines was compared to that seen in normal breast epithelium and breast epithelial cell lines. No difference with regard to bcl-2 and bcl-xL expression was observed between normal breast epithelium and tumor tissue or breast cancer and non-malignant epithelial cell lines. In contrast, bax-alpha, a splice variant of bax, which promotes apoptosis, is expressed in high amounts in normal cell lines and breast tissue, whereas only weak or no expression could be detected in cancer-cell lines and malignant tissue. In contrast to malignant cell lines, which express low levels of bax-alpha, non-malignant epithelial cell lines displaying high amounts of bax-alpha were highly sensitive to induction of programmed cell death by both serum starvation and APO-1/fas (CD95) triggering. We therefore propose that dysregulation of apoptosis contributes to the pathogenesis of breast cancer, at least in part, due to an imbalance between anti-apoptosis genes (such as bcl-2/bcl-x) and apoptosis-promoting genes (bax).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7896458     DOI: 10.1002/ijc.2910600622

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  44 in total

1.  Apoptosis in Endocrine Glands.

Authors:  George Kontogeorgos; Kalman Kovacs
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

2.  bax, but not bcl-2, influences the prognosis of human pancreatic cancer.

Authors:  H Friess; Z Lu; H U Graber; A Zimmermann; G Adler; M Korc; R M Schmid; M W Büchler
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

3.  Overexpression of bax enhances the radiation sensitivity in human breast cancer cells.

Authors:  C Sakakura; E A Sweeney; T Shirahama; Y Igarashi; S Hakomori; H Tsujimoto; T Imanishi; M Ohgaki; J Yamazaki; A Hagiwara; K Sawai; T Yamaguchi; T Takahashi
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

4.  Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types.

Authors:  W Zhu; A Cowie; G W Wasfy; L Z Penn; B Leber; D W Andrews
Journal:  EMBO J       Date:  1996-08-15       Impact factor: 11.598

Review 5.  The Fas counterattack: a molecular mechanism of tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

6.  BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway.

Authors:  T Strobel; L Swanson; S Korsmeyer; S A Cannistra
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

7.  Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas.

Authors:  N Kapucuoglu; L Losi; V Eusebi
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

Review 8.  NF-kappaB, a pivotal transcription factor in silica-induced diseases.

Authors:  Fei Chen; Xianglin Shi
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

9.  Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer.

Authors:  J S de Jong; P J van Diest; R J Michalides; P van der Valk; C J Meijer; J P Baak
Journal:  Mol Pathol       Date:  1998-02

10.  Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice.

Authors:  R C Bargou; C Wagener; K Bommert; M Y Mapara; P T Daniel; W Arnold; M Dietel; H Guski; A Feller; H D Royer; B Dörken
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.